Low-molecular-weight iron dextran

RESTORE AND REPLENISH WITH INFeD

INFeD® (iron dextran injection) is indicated for treatment of adult and pediatric patients of age 4 months and older with documented iron deficiency who have intolerance to oral iron or have had an unsatisfactory response to oral iron.

Doctor and second patient on scale photo

A LEGACY OF BALANCE

Molecule icon

INFeD IS THE ONLY

LOW-MOLECULAR-WEIGHT IRON DEXTRAN

AVAILABLE ON THE MARKET

Check mark icon

INFeD HAS BEEN

FDA APPROVED FOR DECADES

TO TREAT IRON DEFICIENCY*

Shield icon

COMMITMENT TO

PRODUCT QUALITY

AND SAFETY

*INFeD has been FDA approved since 1974 for treatment of adult and pediatric patients of age 4 months and older with documented iron deficiency who have intolerance to oral iron or an unsatisfactory response to oral iron.8

HOW INFeD WORKS TO REPLENISH IRON STORES AND TREAT ID AND IDA

Progress block 1 icon

INFeD is absorbed from the injection site into the capillaries and the lymphatic system10

Progress block 2 icon

Iron dextran in circulation is taken up into the reticuloendothelial system via endocytosis and metabolized in lysosomes, resulting in the release of ferrous iron (Fe[2+])10

Progress block 3 icon

Released Fe(2+) is stored as Fe-ferritin or transported into the blood via ferroportin10

Progress block 4 icon

Once in the blood, Fe(2+) is oxidized to ferric iron (Fe[3+]), bound to transferrin, and transported throughout the body, thereby restoring depleted iron stores and hemoglobin10

Changes in serum ferritin levels represent the changes in calculated cellular non-heme iron levels. After administration of iron
dextran, evidence of a therapeutic response can be seen as an increase in the reticulocyte count.8

Prior to the first INFeD therapeutic dose, administer a test dose. For specific testing instructions for both intramuscular and intravenous use, visit Dosing and Administration page.

INFeD IS WIDELY AVAILABLE ON COMMERCIAL, MEDICARE PART D AND MEDICAID INSURANCE PLANS.*

Iron United States icon

INFeD IS WIDELY AVAILABLE ON COMMERCIAL, MEDICARE PART D AND MEDICAID INSURANCE PLANS.*

*MMIT data as of May 2023. Data are subject to change. Data are not a guarantee of coverage, or partial or full payment, by any payers listed. Actual benefits determined by respective plan administrators. Insurer plans, coverage criteria, and formularies are subject to change without notice. Check each patient's coverage with applicable insurers. AbbVie does not endorse any individual plans. Formulary coverage does not imply efficacy or safety.